Apatinib in Combination With Stereotactic Body Radiation Therapy (SBRT) Treatment for Symptomatic Metastatic Prostate Cancer
Apatinib in Combination With SBRT Treatment for Symptomatic Metastatic
  • Phase

  • Study Type

  • Status

    Completed No Results Posted
  • Intervention/Treatment

    apatinib ...
  • Study Participants

To study safety and efficacy of apatinib in combination of radiotherapy in patients with symptomatic bony disease prostate cancer (SBPC), based on the potential synergistic antitumor activity between Apatinib and Stereotactic Body Radiation Therapy (SBRT).
Study Started
May 10
Primary Completion
Jan 05
Study Completion
Dec 10
Last Update
May 21

Drug Apatinib

Radiation SBRT to symptomatic bony metastatic bony site(s)

RT with apatinib Experimental

selected dose administered PO during and after SBRT

RT alone Active Comparator

symptomatic bony metastatic site(s) receive SBRT less than 5 fractions


Inclusion Criteria:

Histologic diagnosis of adenocarcinoma of the prostate
Metastatic and symptomatic prostate cancer (positive bone scan or measurable disease)
Patients must stop using any herbal product known to decrease PSA levels (eg., saw palmetto and PC-SPES) or any systemic or topical corticosteroid at least 4 weeks prior to screening. Progressive disease must be documented after discontinuation of these products.
Progressive disease after androgen deprivation (or hormone therapy). For patients with measurable disease, progression will be defined by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. For patients with progression in, or without any measurable disease, a positive bone scan and elevated PSA will be required.
Patients receiving bisphosphate therapy must have been on stable doses for at least 4 weeks with stable symptoms prior to enrollment.
No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer).
Prior radiation therapy completed at least 4 weeks prior to enrollment. No prior radiopharmaceuticals (strontium, samarium) within 8 weeks prior to enrollment.

Exclusion Criteria:

History of severe hypersensitivity reactions to drugs formulated with polysorbate 80.
Patients with active autoimmune disease or a history of autoimmune disease that required systemic steroids or immunosuppressive medications, except for patients with vitiligo.
Prior therapy with any anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) antibody.
Active infection requiring therapy.
Concurrent medical condition requiring the use of systemic or topical corticosteroids; systemic or topical corticosteroids must be discontinued at least 4 weeks prior to enrollment. The use of inhaled corticosteroids is acceptable.
No Results Posted